30 closest matches · ranked by relevance
Cardiomyopathy, Hypertrophic Obstructive · Left Ventricular Outflow Tract Obstruction
Primary: Change in Post-exercise Peak LVOT Gradient From Baseline to Week 12 — -89.5; -25.0 mm Hg
Cardiomyopathy, Hypertrophic Obstructive
Primary: Change From Baseline in Post-exercise Left Ventricular Outflow Tract (LVOT) Peak Gradient at Week 30 — -60.6963 millimeters of mercury (mmHg)
Obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Achieving A Clinical Response — 45; 22 Participants
Myocardial Fibrosis · Hypertrophic Cardiomyopathy
Primary: Absolute Change in Serum Markers of Collagen Turnover (Micrograms/L) Over a One-year Follow-up Period in the Spironolactone Group Compared to Placebo. — 2.1; 2.1; 0.7…
HOCM, Hypertrophic Obstructive Cardiomyopathy
Primary: Composite of Decision to Proceed With Septal Reduction Therapy (SRT) and SRT Guideline Eligible at Week 16 — 10; 43 Participants — p=<0.0001
Cardiomyopathy, Hypertrophic
Primary: Change From Baseline in Peak VO2 as Measured by Cardiopulmonary Exercise Test (CPET) — 1.00; 0.39 mL/kg/min — p=0.5506
Non-obstructive Hypertrophic Cardiomyopathy
Primary: Percentage of Participants Who Experienced at Least One Treatment Emergent Adverse Event (TEAE) — 88.9; 90.5; 68.4 percentage of participants
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Primary: Change From Baseline in pVO2 at Week 24 — 1.76; 0.02 mL/kg/min — p=<0.0001
Hypertrophic Cardiomyopathy
Primary: Increase, Stability of, or Decrease in the Decline of Diastolic Function as Reflected by the Global Early Myocardial Relaxation (E') Velocity — -0.06; -0.21 cm/sec…
Obstructive Hypertrophic Cardiomyopathy
Primary: Change From Baseline to Week 30 in Valsalva Left Ventricular Outflow Tract (LVOT) Peak Gradient — -51.05; 19.23 mmHg
Hypertrophic Cardiomyopathy
Primary: Number of Participants With Treatment Emergent Adverse Events and Treatment Emergent Serious Adverse Events — 13; 5 Participants
Hypertrophic Cardiomyopathy
Primary: Recruitment as Assessed by Number of Participants Who Enrolled to the Study — 29; 13 Participants
Hypertrophic Cardiomyopathy
Primary: Percentage Change From Baseline in Extent of Left Ventricular Fibrosis at 1 Year as Assessed by Magnetic Resonance Imaging. — -23; 31 Percentage change in fibrotic…
Hypertrophic Cardiomyopathy (HCM)
Primary: Incidence of Adverse Events (AEs) — 10; 7; 11; 4 Participants
Cardiomyopathy, Hypertrophic
Primary: Change in Peak Oxygen Consumption (Peak VO2) — 1.35; 0.08 mL/kg/min
Duchenne Muscular Dystrophy · Cardiomyopathy
Primary: Number of Participants Experiencing Any of the Adjudicated Events — 0; 0; 0; 0 Participants
Athletes Heart · Left Ventricular Hypertrabeculation
Primary: Thickness of Compacted Myocardial Tissue (cm) — 0.53; 0.56; 0.8; 0.85 cm — p=0.44
Septal Myectomy
Primary: Septal Thickness Measured Before Cardiopulmonary Bypass — 22.9; 22.5 millimeters
Modified Release Oral Formulation · Left Ventricular Systolic Dysfunction · Chronic Heart Failure
Primary: Dose Escalation Phase: Maximum Observed Plasma Concentration (Cmax) of Omecamtiv Mecarbil Following the Last Dose (Day 7) — 193; 201; 171; 492 ng/mL
Hypertrophic Cardiomyopathy
Primary: QT Interval — 462.8 msec
Heart Failure，Congestive · Cardiomyopathies · Left Ventricular Dysfunction
Primary: Primary Endpoint — 12.4; 8.0 percent ejection fraction
Coronary Artery Disease
Primary: Major Adverse Cardiac and Cerebrovascular Event (MACCE) — 23; 10; 3; 1 participants — p=0.80
Sickle Cell Disease
Primary: Frequency of the Diffuse Myocardial Fibrosis Phenotype — 5; 10; 10; 1 Participants
Obesity
Primary: Total Myocardial Oxygen Consumption (MVO2) — 1064; 1202; 947; 835 µmol/min
Post-Infarction Ventricular Septal Defect
Primary: Effectiveness Endpoint 1: Technical Success — 76 Participants
Heart Failure
Primary: Number of Patients Free From Major Adverse Cardiac and Neurological Events (MACNE) at 6 Weeks. — 51 Participants
Obesity · Heart Failure, Diastolic · Metabolic Syndrome
Primary: Change From Baseline at 1 Year in Myocardial Lipid Content — -0.16; -0.18; -0.53; -0.19 %fat/water
Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
Primary: Percentage of Participants With Cardiac Fixation at the Radionuclide Bone Scintigraphy and/or Single Photon Emission Computed Tomography (SPECT): FAS1 — 32.0 Percentage…
Myocardial Ischemia
Primary: Heme Oxygenase-1 (HO-1) Messenger Ribonucleic Acid (mRNA) Levels (Atrial Tissue) — 392.7; 229.8; 10.8 arbitrary units — p==0.001
Stem Cell Transplantation · Ventricular Dysfunction, Left
Primary: Incidence of TE-SAE Define as Composite of Death, Non-fatal MI, Stroke, Hospitalization for Worsening Heart Failure, Cardiac Perforation, Pericardial Tamponade…